Welcome to our dedicated page for MeiraGTx Holdings plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc granted its Chief Medical Officer, Robert K. Zeldin, 100,000 restricted share units (RSUs). Each RSU converts into one ordinary share upon vesting, so the award represents 100,000 underlying ordinary shares.
According to the vesting schedule, 50% of the RSUs will vest on the second anniversary of the grant date, with an additional 25% vesting on each of the third and fourth anniversaries. Following this grant, Zeldin is reported as holding 100,000 RSUs directly.
MeiraGTx Holdings plc reported that its General Counsel and Secretary, Robert J. Wollin, received a grant of 100,000 restricted share units. Each restricted share unit converts into one ordinary share upon vesting. Half the award vests on the second anniversary of the grant date, with 25% vesting on each of the third and fourth anniversaries.
Naylor Stuart reported acquisition or exercise transactions in this Form 4 filing.
MeiraGTx Holdings plc reported that Chief Scientific Officer of Ophthalmology Stuart Naylor received a grant of 70,000 Restricted Share Units. Each RSU represents the right to receive one ordinary share upon vesting. Half of the award vests on the second anniversary of the grant, with 25% vesting on each of the third and fourth anniversaries.
Giroux Richard reported acquisition or exercise transactions in this Form 4 filing.
MeiraGTx Holdings plc granted its CFO & COO, Richard Giroux, 980,000 restricted share units. Each unit represents the right to receive one ordinary share for no cash payment when it vests.
According to the award terms, 50% of the RSUs vest on the second anniversary of the grant date, with 25% vesting on each of the third and fourth anniversaries.
Forbes Alexandria reported acquisition or exercise transactions in this Form 4 filing.
MeiraGTx Holdings plc reported an equity compensation grant to its President and CEO, Alexandria Forbes. On June 25, 2026, Forbes received 980,000 restricted share units (RSUs), each representing the right to receive one ordinary share for no cash payment upon vesting.
According to the disclosure, fifty percent of this RSU award will vest on the second anniversary of the grant date, with twenty-five percent vesting on each of the third and fourth anniversaries. Following this grant, Forbes holds 980,000 RSUs directly, aligning her compensation with the company’s long-term share performance.
MeiraGTx Holdings plc director Debra Yu received a grant of 60,000 restricted share units (RSUs). These RSUs were awarded as a stock-based compensation grant and each unit will convert into one ordinary share when settled.
The RSUs are scheduled to vest in a single installment on the earlier of June 11, 2027, or the day immediately before MeiraGTx’s 2027 annual shareholder meeting. The reporting person has elected that the RSUs become settleable when she ceases to be a director, so actual share delivery will occur at that time. Following this grant, she holds 60,000 RSUs directly.
SHENK THOMAS E reported acquisition or exercise transactions in this Form 4 filing.
MeiraGTx Holdings plc director Thomas E. Shenk received a grant of 69,662 restricted share units. Each unit represents the right to receive one ordinary share upon settlement. The filing shows he now holds 69,662 restricted share units directly after this award.
The units will vest in a single annual installment on the earlier of June 11, 2027 or the day immediately prior to MeiraGTx’s 2027 annual meeting of shareholders. The reporting person elected to have the restricted share units become settleable when he ceases to be a director.
MeiraGTx Holdings plc director Nicole Seligman received a grant of 60,000 restricted share units (RSUs). The award was made on June 11, 2026 and is a form of equity compensation, not an open‑market share purchase or sale.
Each RSU converts into one ordinary share upon settlement. The RSUs vest in a single installment on the earlier of June 11, 2027 or the day immediately prior to MeiraGTx’s 2027 annual shareholder meeting. Seligman elected to have the RSUs become settleable when she ceases to be a director, and following this grant she holds 60,000 RSUs.
MeiraGTx Holdings plc director Neil Mendoza received a grant of 66,641 restricted share units (RSUs) on June 11, 2026. Each RSU converts into one ordinary share upon settlement. The RSUs vest in a single installment on the earlier of June 11, 2027 or the day immediately prior to MeiraGTx’s 2027 annual shareholder meeting. Mendoza elected to have the RSUs become settleable when he ceases to be a director, and his reported RSU holdings after this grant total 66,641 units.
MeiraGTx Holdings plc director Ellen Hukkelhoven received a grant of 60,000 Restricted Share Units (RSUs). These RSUs were awarded as a compensation-related grant with no cash price per unit and are reported as a derivative security linked to the company’s ordinary shares.
Each RSU converts into one ordinary share upon settlement. According to the terms, the RSUs will vest in a single installment on the earlier of June 11, 2027 or the day immediately before MeiraGTx’s 2027 annual shareholder meeting. The reporting person elected to have the RSUs become settleable when she ceases to be a director.